Myomancy ADHD, Dyslexia and Autism

According to the CDC, ADHD sufferers with insurance are three times more likely to be taking medication than those with insurance. In total, the US spends $250 billion a year on medication and now the insurers and Medicaid programs are starting to ask awkward questions about the effectiveness of all these medication. This article on the growing battle between pharmaceutical companies and the organizations that pay for the drugs has an interesting quote:
"When she reviewed Adderall, a stimulant now marketed by Shire Pharmaceuticals Group PLC to treat attention deficit hyperactivity disorder, she noted that one of the major trials included only people who had responded well to Ritalin, another ADHD drug. She thought the move likely improved the results. Dr. Kubota recommended leaving Adderall off Kaiser’s formulary. The physician committees partially overruled her, putting Adderall on the Northern and Southern California formularies but only for patients who failed to respond to another stimulant. Adderall later was added to the preferred list as a first-line treatment after a once-daily formulation went on the market.
A spokesman for Shire, Matt Cabrey, said that the designers of the trial, which was conducted when Adderall belonged to another company, felt that for ethical reasons they should give the drug to people with a "reasonable anticipated reaction." James Swanson, the lead author of the article that described the trial’s results, said the trial was designed to show whether Adderall works faster than Ritalin".
This means that a major trial of Adderall was conducted on people who had already taken Ritalin. This is very different from giving it to people with no experience of other drugs. because the Ritalin users have already been shown to respond well to stimulants so reports of side-effects or poor effectiveness would be reduced.
See also: ADHD, Children and Medication , FDA Concerns Over ADHD Drug Concerta,  ADHD Drug Market: $2.7 billion